期刊
AMERICAN JOURNAL OF CLINICAL NUTRITION
卷 103, 期 6, 页码 1408-1416出版社
OXFORD UNIV PRESS
DOI: 10.3945/ajcn.116.130492
关键词
acylcamitines; cardiovascular disease; Mediterranean diet; metabolomics; PREDIMED
资金
- NIH [HL118264]
- Spanish government
- Institute de Salud Carlos III [RTIC G03/140, RTIC RD 06/0045]
- Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion
- Centro Nacional de Investigaciones Cardiovasculares (CNIC)
- Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional [PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462]
- Ministerio de Ciencia e Innovacion [AGL-2009-13906-C02, AGL2010-22319-C03]
- Fundacion Mapfre
- Consejeria de Salud de la Junta de Andalucia [PI0105/2007]
- Public Health Division of the Department of Health of the Autonomous Government of Catalonia
- Generalitat Valenciana [ACOMP06109, GVA-COMP2010-181, GVACOMP2011-151, CS2010-AP-111, CS2011-AP-042]
- Regional Government of Navarra [P27/2011]
Background: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention. Objectives: We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions. Design: We measured plasma acylcarnitines with the use of high throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevencion con Dieta Mediterranea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected sub cohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study. Results: After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcamitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcamitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group. Conclusions: Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcamitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcamitines and CVD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据